Breast density and mode of detection in relation to breast cancer specific survival: A cohort study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Olsson, Åsa ^a   Sartor, Hanna ^a   Borgquist, Signe ^a   Zackrisson, Sophia ^a   Manjer, Jonas ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; ASYMPTOMATIC DISEASE; AXILLARY LYMPH NODE; BODY MASS; BREAST CANCER; BREAST DENSITY; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; COHORT ANALYSIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; RADIOLOGICAL PARAMETERS; SWEDEN; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84899066635     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-229     Document Type: Article

References (49)

1. McCormack VA, dos Santos SI. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006, 15(6):1159-1169. 10.1158/1055-9965.EPI-06-0034, 16775176.
2. Buist DS, Porter PL, Lehman C, Taplin SH, White E. Factors contributing to mammography failure in women aged 40-49 years. J Natl Cancer Inst 2004, 96(19):1432-1440. 10.1093/jnci/djh269, 15467032.
3. Carney PA, Miglioretti DL, Yankaskas BC, Kerlikowske K, Rosenberg R, Rutter CM, Geller BM, Abraham LA, Taplin SH, Dignan M, Cutter G, Ballard- Barbash R. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003, 138(3):168-175. 10.7326/0003-4819-138-3-200302040-00008, 12558355.
4. Olsen AH, Bihrmann K, Jensen MB, Vejborg I, Lynge E. Breast density and outcome of mammography screening: a cohort study. Br J Cancer 2009, 100(7):1205-1208. 10.1038/sj.bjc.6604989, 2669986, 19293800.
5. Chiu SY, Duffy S, Yen AM, Tabar L, Smith RA, Chen HH. Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening. Cancer Epidemiol Biomarkers Prev 2010, 19(5):1219-1228. 10.1158/1055-9965.EPI-09-1028, 20406961.
6. Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, Tsao M-S, Khokha R, Martin L, Boyd N. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers && prevention, Cancer Epidemiol biomarkers and prevention 2005, 14(2):343-349.
7. Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S. Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst 2010, 102(16):1224-1237. 10.1093/jnci/djq239, 2923218, 20616353.
8. Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 2000, 11(7):653-662. 10.1023/A:1008926607428, 10977110.
9. Tamimi RM, Hankinson SE, Colditz GA, Byrne C. Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomarkers Prev 2005, 14(11 Pt 1):2641-2647.
10. Lam PB, Vacek PM, Geller BM, Muss HB. The association of increased weight, body mass index, and tissue density with the risk of breast carcinoma in Vermont. Cancer 2000, 89(2):369-375. 10.1002/1097-0142(20000715)89:2<369::AID-CNCR23>3.0.CO;2-J, 10918168.
11. Vacek PM, Geller BM. A prospective study of breast cancer risk using routine mammographic breast density measurements. Cancer Epidemiol Biomarkers Prev 2004, 13(5):715-722.
12. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003, 95(1):30-37. 10.1093/jnci/95.1.30, 12509398.
13. Breast Cancer Screening 2002, Lyon(France), HoCP IARC.
14. van Gils CH, Otten JD, Verbeek AL, Hendriks JH, Holland R. Effect of mammographic breast density on breast cancer screening performance: a study in Nijmegen, The Netherlands. J Epidemiol Community Health 1998, 52(4):267-271. 10.1136/jech.52.4.267, 1756693, 9616416.
15. Porter GJ, Evans AJ, Cornford EJ, Burrell HC, James JJ, Lee AH, Chakrabarti J. Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival. AJR Am J Roentgenol 2007, 188(3):676-683. 10.2214/AJR.05.1950, 17312053.
16. Gierach GL, Ichikawa L, Kerlikowske K, Brinton LA, Farhat GN, Vacek PM, Weaver DL, Schairer C, Taplin SH, Sherman ME. Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst 2012, 104(16):1218-1227. 10.1093/jnci/djs327, 3611814, 22911616.
17. Maskarinec G, Pagano IS, Little MA, Conroy SM, Park SY, Kolonel LN. Mammographic density as a predictor of breast cancer survival: the Multiethnic Cohort. Breast Cancer Res 2013, 15(1):R7. 10.1186/bcr3378, 3672725, 23339436.
18. Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004, 292(9):1064-1073. 10.1001/jama.292.9.1064, 15339900.
19. Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009, 101(8):1338-1344. 10.1038/sj.bjc.6605317, 2768460, 19773756.
20. Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, Duffy SW. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?. Br J Cancer 2008, 98(11):1741-1744. 10.1038/sj.bjc.6604368, 2410118, 18506175.
21. Olsson A, Borgquist S, Butt S, Zackrisson S, Landberg G, Manjer J. Tumour-related factors and prognosis in breast cancer detected by screening. Br J Surg 2012, 99(1):78-87. 10.1002/bjs.7757, 22068957.
22. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo diet and cancer study, design and feasibility. J Intern Med 1993, 233(1):45-51. 10.1111/j.1365-2796.1993.tb00647.x, 8429286.
23. Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M, Mattisson I, Berglund G. The Malmo diet and cancer study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 2001, 10(6):489-499. 10.1097/00008469-200112000-00003, 11916347.
24. Zackrisson S. Non-attendance in breast cancer screening is associated with unfavourable socio-economic circumstances and advanced carcinoma. Int J Cancer 2004, 108:754-760. 10.1002/ijc.11622, 14696103.
25. Causes of death 2010. National Board of Health and Welfare 2011, http://www.socialstyrelsen.se/riktlinjer/nationellascreeningprogram/brostcancer_screeningmedmammog.
26. World Health Organization. Histological typing of breast tumours. Second edition. Geneva, 1981. Ann Pathol 1982, 2:91-105.
27. Elston CW, EIO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079, EIO.
28. Borgquist S, Djerbi S, Ponten F, Anagnostaki L, Goldman M, Gaber A, Manjer J, Landberg G, Jirstrom K. HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. Int J Cancer 2008, 123(5):1146-1153. 10.1002/ijc.23597, 18528862.
29. Bröst Cancer 2009, Astra Zeneca AB, Jönsson P-E.
30. American College of Radiology. http://www.acr.org.
31. Freedman LSGBI, Schatzkin A. Statistic validation of intermediate endpoints for chronic diseases. Stat Med 1992, 11:167-178. 10.1002/sim.4780110204, 1579756.
32. Dödsorsaksstatisktik, Historik, produktionsmetoder och tillförlitlighet. National Board of Health and Welfare 2010, http://www.socialstyrelsen.se/publikationer2011/2011-6-7.
33. Johansson LA, Bjorkenstam C, Westerling R. Unexplained differences between hospital and mortality data indicated mistakes in death certification: an investigation of 1,094 deaths in Sweden during 1995. J Clin Epidemiol 2009, 62(11):1202-1209. 10.1016/j.jclinepi.2009.01.010, 19364635.
34. Yaffe MJ. Mammographic density. Measurement of mammographic density. Breast Cancer Res 2008, 10(3):209. 10.1186/bcr2102, 2481498, 18598375.
35. Harvey JA, Gard CC, Miglioretti DL, Yankaskas BC, Kerlikowske K, Buist DS, Geller BA, Onega TL. Reported mammographic density: film-screen versus digital acquisition. Radiology 2013, 266(3):752-758. 10.1148/radiol.12120221, 3579169, 23249570.
36. Demark-Wahnefried W, Campbell KL, Hayes SC. Weight management and its role in breast cancer rehabilitation. Cancer 2012, 118(8 Suppl):2277-2287. 3812811, 22488702.
37. Statistisk Årsbok. 2012, Statistiska Centralbyrån, http://www.scb.se/statistik/_publikationer/OV0904_2012A01_BR_00_A01BR1201.pdf.
38. Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, White E. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000, 92(13):1081-1087. 10.1093/jnci/92.13.1081, 10880551.
39. Ma L, Fishell E, Wright B, Hanna W, Allan S, Boyd NF. Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst 1992, 84(10):781-785. 10.1093/jnci/84.10.781, 1573665.
40. Eriksson L, Czene K, Rosenberg LU, Tornberg S, Humphreys K, Hall P. Mammographic density and survival in interval breast cancers. Breast Cancer Res 2013, 15(3):R48. 10.1186/bcr3440, 23786804.
41. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 2011, 13(6):223. 10.1186/bcr2942, 3326547, 22114898.
42. Varghese JS, Thompson DJ, Michailidou K, Lindstrom S, Turnbull C, Brown J, Leyland J, Warren RM, Luben RN, Loos RJ, Wareham NJ, Rommens J, Martin LJ, Vachon CM, Scott CG, Atkinson EJ, Couch FJ, Apicella C, Southey MC, Stone J, Li J, Eriksson L, Czene K, Boyd NF, Hall P, Hopper JL, Tamimi RM. Mammographic breast density and breast cancer: evidence of a shared genetic basis. Cancer Res 2012, 72(6):1478-1484. 10.1158/0008-5472.CAN-11-3295, 3378688, 22266113.
43. Brisson J, Brisson B, Cote G, Maunsell E, Berube S, Robert J. Tamoxifen and mammographic breast densities. Cancer Epidemiol Biomarkers Prev 2000, 9(9):911-915.
44. Chow CK, Venzon D, Jones EC, Premkumar A, O'Shaughnessy J, Zujewski J. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 2000, 9(9):917-921.
45. Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008, 10(1):201. 10.1186/bcr1831, 2374950, 18226174.
46. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432(7015):332-337. 10.1038/nature03096, 3050735, 15549095.
47. Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res 2003, 5(5):R129-R135. 10.1186/bcr622, 314426, 12927043.
48. Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E, Khokha R, Boyd NF. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 2001, 10(3):243-248.
49. Wiseman BS, Werb Z. Stromal effects on mammary gland development and breast cancer. Science 2002, 296(5570):1046-1049. 10.1126/science.1067431, 2788989, 12004111.